Redmile Group, LLC Infla Rx N.V. Transaction History

Redmile Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $6.68 Million - $113 Million	-2,182,638 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $4.59 Million - $7.16 Million	147,238 Added 7.23%	2,182,638 $82.5 Million
Q4 2018 Feb 14, 2019	BUY	$23.33 - $36.37 $244,964 - $381,885	10,500 Added 0.52%	2,035,400 $74 Million
Q3 2018 Nov 14, 2018	SELL	$29.34 - $35.0 $82,152 - $98,000	-2,800 Reduced 0.14%	2,024,900 $69.5 Million
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $32.2 Million - $48.8 Million	1,176,600 Added 138.24%	2,027,700 $65.4 Million
Q1 2018 May 15, 2018	SELL	$20.21 - $32.0 $125,302 - $198,400	-6,200 Reduced 0.72%	851,100 $0
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $12.5 Million - $20.6 Million	857,300	857,300 $18 Million

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $99M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.